Germán Camejo
Affiliations: | Instituto Venezolano de Investigaciones Cientificas, Parroquia Macarao, Miranda, Venezuela |
Google:
"Germán Camejo"Parents
Sign in to add mentor
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pedrelli M, Parini P, Kindberg J, et al. (2021) Vasculoprotective Properties of Plasma Lipoproteins from Brown Bears (Ursus arctos). Journal of Lipid Research. 100065 |
| Ahmed O, Littmann K, Gustafsson U, et al. (2018) Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. Journal of the American Heart Association. 7: e009876 |
| Garcés Da Silva MF, Guarin YA, Carrero Y, et al. (2018) Postprandial Hypertriglyceridemia Is Associated with the Variant 54 Threonine Gene. Journal of Cardiovascular Development and Disease. 5 |
| Hurt-Camejo E, Camejo G. (2018) ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker. Journal of Cardiovascular Development and Disease. 5 |
| Garcés MF, Guarin Y, Carrero Y, et al. (2016) Fat Intolerance in Apparently Healthy Individuals with Normal Fasting Lipoproteins Is Associated with Markers of Cardiovascular Risk. The Journal of Applied Laboratory Medicine. 1: 250-259 |
| Garcés MF, Guarin Y, Carrero Y, et al. (2016) Fat Intolerance in Apparently Healthy Individuals with Normal Fasting Lipoproteins Is Associated with Markers of Cardiovascular Risk The Journal of Applied Laboratory Medicine: An Aacc Publication. 1: 250-259 |
| Umaerus M, Rosengren B, Fagerberg B, et al. (2012) HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect. Atherosclerosis. 225: 115-20 |
| Camejo G. (2010) Lysophospholipids: effectors mediating the contribution of dyslipidemia to calcification associated with atherosclerosis. Atherosclerosis. 211: 36-7 |
| Davidsson P, Hulthe J, Fagerberg B, et al. (2010) Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology. 30: 156-63 |
| Van Der Hoorn JWA, Jukema JW, Havekes LM, et al. (2009) The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice British Journal of Pharmacology. 156: 1067-1075 |